WASHINGTON — On Thursday, the Trump administration organized a private press conference so that a senior Food and Drug Administration official could anonymously criticize an experimental Huntington’s disease treatment made by the company UniQure.
In the past, when faced with a controversial regulatory matter, the agency would often organize public gatherings with an independent panel of advisors, known in industry parlance as an advisory committee meeting, or adcomm. Patients, doctors, and other interested parties were given an opportunity to comment. They gained a transparent look inside the scientific dialogue between company leaders and regulators, who would present their own analysis of applications for medical product approvals.
STAT Plus: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad
UniQure announced last fall that a clinical trial showed its treatment dramatically slowed the progression of Huntington’s disease. The company seemed confident it could apply for approval. Then, the FDA said it wasn’t convinced.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
